Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2016

01-08-2016 | Original Article

Amoxicillin–Clavulanate-Induced Liver Injury

Authors: Andrew S. deLemos, Marwan Ghabril, Don C. Rockey, Jiezhun Gu, Huiman X. Barnhart, Robert J. Fontana, David E. Kleiner, Herbert L. Bonkovsky, Drug-Induced Liver Injury Network (DILIN)

Published in: Digestive Diseases and Sciences | Issue 8/2016

Login to get access

Abstract

Background and Aims

Amoxicillin–clavulanate (AC) is the most frequent cause of idiosyncratic drug-induced injury (DILI) in the US DILI Network (DILIN) registry. Here, we examined a large cohort of AC-DILI cases and compared features of AC-DILI to those of other drugs.

Methods

Subjects with suspected DILI were enrolled prospectively, and cases were adjudicated as previously described. Clinical variables and outcomes of patients with AC-DILI were compared to the overall DILIN cohort and to DILI caused by other antimicrobials.

Results

One hundred and seventeen subjects with AC-DILI were identified from the cohort (n = 1038) representing 11 % of all cases and 24 % of those due to antimicrobial agents (n = 479). Those with AC-DILI were older (60 vs. 48 years, P < 0.001). AC-DILI was more frequent in men than women (62 vs. 39 %) compared to the overall cohort (40 vs. 60 %, P < 0.001). The mean time to symptom onset was 31 days. The Tb, ALT, and ALP were 7 mg/dL, 478, and 325 U/L at onset. Nearly all liver biopsies showed prominent cholestatic features. Resolution of AC-DILI, defined by return of Tb to <2.5 mg/dL, occurred on average 55 days after the peak value. Three female subjects required liver transplantation, and none died due to DILI.

Conclusion

AC-DILI causes a moderately severe, mixed hepatocellular–cholestatic injury, particularly in older men, unlike DILI in general, which predominates in women. Although often protracted, eventual apparent recovery is typical, particularly for men and usually in women, but three women required liver transplantation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934, 1934 e1921–1924. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934, 1934 e1921–1924.
2.
go back to reference Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.CrossRefPubMed Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.CrossRefPubMed
3.
go back to reference Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425, 1425 e1411–1413; quiz e1419–e1420. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425, 1425 e1411–1413; quiz e1419–e1420.
4.
go back to reference Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–928.CrossRefPubMed Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–928.CrossRefPubMed
5.
go back to reference Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis. 1999;3:433–464, vii. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis. 1999;3:433–464, vii.
6.
go back to reference Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95–132, vii. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95–132, vii.
7.
go back to reference Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol. 2007;13:6087–6089.CrossRefPubMedPubMedCentral Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol. 2007;13:6087–6089.CrossRefPubMedPubMedCentral
8.
9.
go back to reference Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci. 2005;50:1785–1790.CrossRefPubMed Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci. 2005;50:1785–1790.CrossRefPubMed
10.
go back to reference Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ Jr, Agrawal RM. Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens–Johnson syndrome. Ann Pharmacother. 1999;33:560–564.CrossRefPubMed Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ Jr, Agrawal RM. Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens–Johnson syndrome. Ann Pharmacother. 1999;33:560–564.CrossRefPubMed
11.
go back to reference Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68.CrossRefPubMedPubMedCentral Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–68.CrossRefPubMedPubMedCentral
12.
go back to reference Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459.CrossRefPubMed Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459.CrossRefPubMed
13.
go back to reference Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.CrossRefPubMedPubMedCentral Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.CrossRefPubMedPubMedCentral
14.
go back to reference Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13:1328–1336.e2.CrossRefPubMed Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13:1328–1336.e2.CrossRefPubMed
15.
go back to reference Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin–clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856.CrossRefPubMed Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin–clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44:850–856.CrossRefPubMed
16.
go back to reference Reddy KR, Brillant P, Schiff ER. Amoxicillin–clavulanate potassium-associated cholestasis. Gastroenterology. 1989;96:1135–1141.CrossRefPubMed Reddy KR, Brillant P, Schiff ER. Amoxicillin–clavulanate potassium-associated cholestasis. Gastroenterology. 1989;96:1135–1141.CrossRefPubMed
17.
go back to reference Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin–clavulanate–induced hepatitis. Gastroenterology. 1999;117:1181–1186.CrossRefPubMed Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin–clavulanate–induced hepatitis. Gastroenterology. 1999;117:1181–1186.CrossRefPubMed
18.
19.
go back to reference Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015;180:40–51.CrossRefPubMedPubMedCentral Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015;180:40–51.CrossRefPubMedPubMedCentral
20.
go back to reference Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin–clavulanate–induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.CrossRefPubMedPubMedCentral Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin–clavulanate–induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.CrossRefPubMedPubMedCentral
21.
go back to reference Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin–clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.CrossRefPubMedPubMedCentral Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin–clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.CrossRefPubMedPubMedCentral
22.
go back to reference Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–819.CrossRefPubMed Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–819.CrossRefPubMed
23.
go back to reference Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22:784–795.CrossRefPubMedPubMedCentral Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22:784–795.CrossRefPubMedPubMedCentral
24.
go back to reference de Haan F. Stricker BH [Liver damage associated with the combination drug amoxicillin-clavulanic acid (Augmentin)]. Ned Tijdschr Geneeskd. 1997;141:1298–1301.PubMed de Haan F. Stricker BH [Liver damage associated with the combination drug amoxicillin-clavulanic acid (Augmentin)]. Ned Tijdschr Geneeskd. 1997;141:1298–1301.PubMed
25.
go back to reference Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162:638–640.PubMed Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162:638–640.PubMed
26.
go back to reference O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47:717–720.CrossRefPubMedPubMedCentral O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47:717–720.CrossRefPubMedPubMedCentral
27.
go back to reference Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327–1332.CrossRefPubMed Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327–1332.CrossRefPubMed
Metadata
Title
Amoxicillin–Clavulanate-Induced Liver Injury
Authors
Andrew S. deLemos
Marwan Ghabril
Don C. Rockey
Jiezhun Gu
Huiman X. Barnhart
Robert J. Fontana
David E. Kleiner
Herbert L. Bonkovsky
Drug-Induced Liver Injury Network (DILIN)
Publication date
01-08-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4121-6

Other articles of this Issue 8/2016

Digestive Diseases and Sciences 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.